Abstract
As the economic downturn chokes spin-outs from academia, a spate of newly minted university-industry partnerships are springing up. Failing to address the financial conflicts in such partnerships could spell trouble for both faculty and drug companies. Jim Kling investigates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
